Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Merck L-830982 · 1 trial · 1 indication
The N-back task is a sequential-letter memory task for which working memory load is varied, as the respondent must indicate when the current stimulus matches the one from 'n' steps earlier in the sequence. The dependent measure for the N-back task was performance in the 2-back condition, which provides the best index of performance and dorsolateral prefrontal cortex disturbances in subjects with schizophrenia.
The N-back task is a sequential-letter memory task for which working memory load is varied, as the respondent must indicate when the current stimulus matches the one from 'n' steps earlier in the sequence. The dependent measure for the N-back task was performance in the 2-back condition, which provides the best index of performance and dorsolateral prefrontal cortex disturbances in subjects with schizophrenia.
For the AX Continuous Performance Test, subjects are required to maintain an attentional set across a delay interval in order to overcome a prepotent response tendency (target responses are required when an X is presented but only in the context of a preceding A; non-target conditions are AY, BX and BY). The dependent measure was d-prime at the long delay (calculated as AX hits minus BX false alarms, which is particularly sensitive to context processing impairments in individuals with schizophrenia.
The POP task is a cued stimulus-response reversal paradigm that, similar to the AX Continuous Performance Test, requires increases in cognitive control through the maintenance and use of context information to overcome prepotent response tendencies.
The POP task is a cued stimulus-response reversal paradigm that, similar to the AX Continuous Performance Test, requires increases in cognitive control through the maintenance and use of context information to overcome prepotent response tendencies.
| Arm | Type | Description |
|---|---|---|
| Merck L-830982 | EXPERIMENTAL | - |
| Sugar pill | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Merck L-830982 | DRUG | The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy. |
| Placebo | DRUG | Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug. |
Inclusion Criteria: * Male participants * Between the ages of 18 and 50 * Meet diagnostic criteria for schizophrenia or schizoaffective disorder * Are clinically stable for a minimum of 3 months on current dose of medication * Are unemployed (i.e., work less than 20 hours per week at competitive em...
Merck L-830982 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 2 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
Merck L-830982 is a small molecule designed to modulate the GABA-A alpha2/3 receptor subtype. This target is believed to play a role in the neurobiological pathways associated with schizophrenia, and the drug aims to address symptoms by acting on this specific receptor.
Merck L-830982 is being developed by Merck & Company, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's potential as a treatment for schizophrenia.
Merck L-830982 is in Phase 2 clinical development. It has completed one Phase 2 trial, and the drug remains investigational, meaning it is not yet approved for use outside of clinical research settings.
Merck L-830982 has been studied in a completed Phase 2 clinical trial registered as NCT00129441, titled "Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study." This randomized, double-blind, placebo-controlled trial enrolled 16 male participants with schizophrenia in the United States.
Merck L-830982 is not the same as GABA-A alpha2/3; rather, GABA-A alpha2/3 is the molecular target that the drug acts on. The drug is designed to interact with this receptor subtype, which is a focus of its mechanism of action in treating schizophrenia.